Nancy Chang, Ph.D is Ansun’s CEO and Chairperson of the Board and has served as a Director of Ansun since 2011. Nancy was the Chairperson and Senior Managing Director of Caduceus Asia Partners at OrbiMed Advisors from 2007 to 2012. From 1987 to 2007, Dr. Chang served as Co-Founder, President and Chairman of Tanox, Inc., which was sold to Genentech in 2007. Prior to founding Tanox, Dr. Chang held several leadership positions at Centocor, now a division of Johnson & Johnson. She was also an Associate Professor at Baylor College of Medicine. She has served on the board of a number of companies, including SciClone Pharmaceuticals, Inc., Charles River Laboratories International, Inc., Applied Optoelectronics Inc. Nancy received her Doctorate in Biological Chemistry from Harvard University.
Dr. Nancy Chang, CEO and Chairperson of the Board
Dr. Yining Zhao, Ph.D, MBA, President and Chief Operating Officer
Dr. Yining Zhao is currently President and Chief Operating Officer at Ansun Biopharma. He is also Chairman and co-founder of Transcenta Holding. He was Venture Partner at Lilly Asia Ventures during 2015-2018. Prior to his entrepreneurial career, Dr. Zhao worked in the areas of Strategy Management and Business Development at multinational biopharmaceutical companies for more than 20 years. He was Executive Strategy Director at Global Commercial Operations at Amgen in Thousand Oaks, California. Before that he was the Asia Strategy Lead at Pfizer in Boston.
Dr. Zhao received his B.S. in Pharmaceutical Sciences from Fudan University, Ph.D. in Analytical Chemistry from Ghent University, and MBA from MIT. He has been a member of the executive board of the MIT Sloan School of Management since 2017.
Dr. George Wang, CTO
George Y. Wang, Sc.D. has served as Senior Technical Advisor and then Chief Technical Officer at Ansun Biopharma since April 2013. He was the Managing Director of A-Bio Pharma Pte Ltd. in charge of all operations from 2004 until 2008. Prior to that, he was at Tanox, Inc. from 1991 until 2002 and served as Vice President of Process Development and Production. Dr. Wang held various engineering positions at IDEC Pharmaceuticals, BP Amoco Corporation and MGI Pharmaceuticals, Inc. Dr. Wang received his Sc.D. in Biochemical Engineering from Massachusetts Institute of Technology
Dr. Haiyan Jiang, Chief Scientific Officer
Haiyan Jiang, PhD, joined Ansun in Oct 2020 as Chief Scientific Officer. In Sept 2018 – Sept 2020, Dr. Jiang was the co-founder and Head of R&D at Geneception, a cell and gene therapy company. From Jan 2016 to Aug 2018, she was VP of Preclinical Sciences at Editas Medicine, overseeing the translation of CRISPR/Cas9 therapeutics from research to IND. From Oct 2010 to Dec 2015, Dr. Jiang was Director then Sr Director at Biogen, where she led preclinical development and clinical pharmacology for both Alprolix and Elocate. She also initiated the research of BIVV001, and led the research collaborations on in vivo lentiviral gene therapy and ex vivo genome editing in HSC cells. Prior to Biogen, Dr. Jiang’s work included research and development of Jivi at Bayer in 2005 – 2010, and AAV-mediated gene therapy for Hemophilia at Avigen in 2001-2005. She received BS in biochemistry at Fudan University in Shanghai, China, PhD in oncology at University of Wisconsin-Madison, and postdoctoral training at University of California, San Francisco.
Dr. Shuanglian Li, Senior Vice President
Shuanglian Li, MD Ph.D is Senior Vice President, Clinical Development of oncology and autoimmune diseases at Ansun Biopharma, overseeing the company’s clinical development strategies and execution of clinical trials. Dr. Li has over 15 years of drug development industrial experience across multiple therapeutic areas in both large pharma, small-mid size and start-up companies. Prior to joining Ansun, Dr. Li was the Head of Clinical Development at Geneception, where she was responsible for the clinical development strategy of hemophilia and metabolic disease gene therapy. Dr. Li assumed roles of increasing responsibility in Oncology Therapeutic Area Unit at Takeda and Ariad (acquired by Takeda in 2017) since 2015, where she led the development of the first in class EGFR exon 20 insertion inhibitor Mobocertinib from FIH to pivotal clinical trials supporting NDA. Dr. Li also holds various positions at Biogen, Pfizer and Sugen (acquired by Pfizer in 2003), and had contributed to the approvals of Eloctate and Alprolix, and Sunitinib. During her career, Dr. Li has been involved in all phases of drug development from preclinical drug safety to late-stage drug development and post-marketing clinical research; Specialized in clinical development of Hematology and Oncology products.
Dr. Li received her M.D from Beijing Medical University (Peking University since 2001) and her Ph.D in Pharmaceutical Science from University of California at San Francisco.
SVP of Clinical Development and Operation
Dr. Ho joined Ansun in 2017 as its V.P. of Clinical Development. She is also the V.P. of R&D and Clinical Trial Development at Steminent US, Inc., which is a company involved in stem cell therapeutics. She has a long list of accomplishments and awards including: being a Professor at the Graduate Institute of Clinical Medicine, Taipei Medical University; a Director of Medical Research at the Wan Fang Medical Center, Taipei Medical University, Taiwan; being an editorial board member or review on over 10 scientific journals; receiving the Best Clinical Research Award from Taipei Medical University four out of the last seven years; and having 6 patents and publishing over 40 peer reviewed scientific publications. She received her M.D. in 1998 from National Taiwan University and her Ph.D. in Biopharmaceutical Science from the Institute of Biopharmaceutical Science, National Yang-Ming University.
Board of Directors
Dr. Nancy Chang
Nancy Chang, Ph.D is the Chairperson of the Board and has served as Director of Ansun since 2011. She is a pioneer of the biopharmaceutical industry. She was the Chairperson and Senior Managing Director of Caduceus Asia Partners at OrbiMed Advisors from 2007 to 2012. From 1987 to 2007, Dr. Chang served as Co-Founder, President and Chairman of Tanox, Inc., which was sold to Genentech in 2007. Prior to founding Tanox, Dr. Chang held several leadership positions at Centocor, now a division of Johnson & Johnson. She was also an Associate Professor at Baylor College of Medicine. She has served on the board of a number of companies, including SciClone Pharmaceuticals, Inc., Charles River Laboratories International, Inc., Applied Optoelectronics Inc. Nancy received her Doctorate in Biological Chemistry from Harvard University.
Dr. Allen Chao
Allen Chao, Ph.D has served as a Director at Ansun since 2010. Dr. Chao is a pioneer in the life sciences industry. Since January 2008, Dr. Chao has been Chairman of Newport Healthcare Advisors, LLC, a healthcare investment management and consulting company. Dr. Chao was a co-founder of Watson Pharmaceuticals, Inc. (now Actavis plc), a specialty pharmaceutical company, serving as a director from 1985 to May 2008, Chairman of the board of directors from May 1996 to May 2008, and Chief Executive Officer from 1985 to September 2007. While at Watson, Dr. Chao oversaw the company’s growth, through internal R&D, licensing and acquisitions of pharmaceutical products and technologies, as well as mergers and acquisition activities. Dr. Chao received a Ph.D in industrial and physical pharmacy from Purdue University in 1973. In May of 2000, he received the degree of Doctor of Science from Purdue.
Dr. Michael Chang
Michael Chang, Ph.D has served as Director of Ansun since 2014. He is an accomplished biopharmaceutical scientist, executive and entrepreneur. In 1994, Dr. Chang established Pharmanex, a health products company, which was acquired by NuSkin Enterprises, where he was appointed Chief Scientific Advisor. Prior to this, he founded Cinogen in 1993. Dr. Chang was formerly the Director of Medical Chemistry at Rhone-Poulenc Rorer and Deputy Director of Medicinal Chemistry at Merck, Sharpe & Dohme (US Merck). Dr. Chang received his Ph.D. in Organic Chemistry from Brandeis University, and conducted postdoctoral research at MIT. He received his BS in Chemistry from Fu Jen Catholic University in Taiwan. He holds 39 patents and has published more than 69 scientific papers in peer reviewed journals.
Dr. Yi Shi
Yi Shi, Ph.D has served as Director of Ansun since April 2018. He is the Founder and Managing Partner of Lilly Asia Ventures, a biomedical venture capital firm with focus on China and cross-border opportunities. Prior to his current role, Yi worked at Eli Lilly and Company in business development licensing and corporate ventures. His education includes a Ph.D. in Biochemistry and a Master of Business Administration, both from Duke University. He also has a Bachelor of Sciences in Biology from the University of Science and Technology of China.
Dr. Michael Chao
Michael Chao, MD is the Senior Managing Director of Relativity Healthcare Partners, LLC, a family office investment group dedicated to providing capital to companies developing promising technologies and/or offering novel services to address unmet needs. As a financier, Dr. Chao concentrates on investments that build preeminent healthcare companies. He has been involved with investments in various companies, including LensGen, Tanvex BioPharma, TenNor Therapeutics, EarLens, and Orphomed. He has served on the Board of Directors for MidLabs, BioAnalytix, and Owl Biomedical through successful exits. Furthermore, Dr. Chao maintains a direct link to the healthcare community as a staff physician at the US Department of Veterans Affairs healthcare system, providing medical and surgical care for veterans and combat veterans from current and prior military conflicts. Dr. Chao has served on Children’s Hospital of Orange County (CHOC) Foundation Board, where he chaired the Transformational Philanthropic Venture Funding Committee, which on supports innovative ideas in pediatric health. Dr. Chao received his MD from University of California, Irvine and his BA in Biology from the University of Pennsylvania.
Mr. Wu has served as Director of Ansun since July of 2018. Mr. Aimin Wu is the President and Managing Partner of Sinopharm Capital. Prior to that, Mr. Wu served as the Chief Financial Officer of Sinopharm Group Co. Ltd. from July 2003 to December 2006. From 2007 to 2012, Mr. Wu served as the Vice President of Sinopharm Group Co. Ltd. In addition, Mr. Wu was a Director of Accord Pharma from January 2005 to April 2014, a Director of National Medicines from December 2005 to December 2008 and a supervisor of National Medicines from May 2009 to December 2011. Mr. Wu has nearly 20 years of working experience in Chinese and international capital market operations, pharmaceutical industry strategic development, mergers and acquisitions, restructurings, business development and financial management. Mr. Wu is a qualified accountant in the PRC. He obtained an Executive Master of Business Administration degree from Shanghai Jiao Tong University in December 2006, and a Bachelor’s degree in Engineering, Majoring in Economy, from Hunan University in July 1992.
Donald Payne, MBA, CPA has served as a Director at Ansun since April 2018. For the past 27 years Mr. Payne has held senior operating and financial positions in early-stage biopharmaceutical and medical device companies. His operations experience includes authoring IND and IDE filings with the FDA, managing US and non-US clinical trials in oncology, establishing cGMP manufacturing operations, and managing preclinical efficacy and toxicology programs. Mr. Payne has co-authored 9 scientific publications and is a co-inventor of two issued and one pending patent applications. He has served as a director of public and private early stage companies, including as the Chairman of the Audit Committee of a Nasdaq-listed company. As the chief financial officer of early stage companies, he has participated in various public and private financings and listings on NYSE and Nasdaq. He currently consults with biopharmaceutical and medical device companies focused in oncology. Mr. Payne is a Summa Cum Laude graduate of Rice University with a Masters in Business Administration (1992) and a Summa Cum Laude graduate of Texas A&M University (1976) with a Bachelor in Business Administration. Mr. Payne is a licensed CPA in Texas.
Mr. Chenn is a well-known entrepreneur in China. Before returning to China, Mr. Chenn worked at Emerson Electric, McKinsey & Co. and Oracle Corp. in the U.S. At Oracle, Mr. Chenn worked as a Product Marketing Manager, Senior Manager/Director and Director of the Healthcare & Education Sectors for Greater China. Mr. Chenn returned to China in 2005 and founded YuanTel Co., YuanTech Co., OrthoGuard Physicians Group and China Century Group. He has successfully built China Century Group into a multi-billion dollar conglomerate with businesses in the technology, energy, financial, culture & travel and healthcare industries and operations in China, the U.S. and Southeast Asia. Mr. Chenn is also actively involved in social and philanthropy activities. He is both a council member and a member of the Global Advisory Committee for the University of Chicago Booth School of Business, Vice Chairman of the Green Energy Foundation, Vice Chairman of the Board of Trustees of Beijing Institute of Technology, Executive Director of the Board of Trustees of Beijing Film Academy, member of the Asia Development Council at Yale University and member of the Board of Directors for The Culver Academy. His business achievements and generous giving to the society have won him numerous honors including “Top Ten Figures in China for Economic Development” and “Innovation Leader in the Chinese Economy”. Mr. Chenn holds an MBA degree from the University of Chicago Booth School of Business, and a B.S. degree in Engineering from Beijing Institute of Technology.
Dr. Karen Liu is a founding partner of 3E Bioventures Capital, a healthcare focused venture investment firm which invests in new drugs and innovative devices and diagnostics. Prior to 3E, Dr. Karen Liu was a partner of Kaiwu Capital and Managing Director at CRCI Capital, always covering healthcare investing. Dr. Liu received her Ph.D in Immunology from Harvard University, Master of Medical Sciences degree from Harvard University, and Bachelor of Sciences degree from Cornell University. She also received an EMBA degree from CKGSB – Chungkong Graduate School of Business in China.